Sunshine Biopharma Inc Overview
Industry: Drug Manufacturers Specialty & Generic
Sector: Healthcare
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada. Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, l Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Sunshine Biopharma Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $36.3M (reported). Net loss was -$6.
Revenue
$36.3M
reported
Net loss
-$6
reported
What changed
- Revenue reported to $36.3M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings material
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
FORM 10-Q FOR MAR 2026
May 13, 2026
SEC filing
CURRENT REPORT
Apr 09, 2026
SEC filing
FORM 10-K FOR DEC 2025
Apr 03, 2026
SEC filing
FORM 10-Q FOR SEP 2025
Nov 13, 2025
SEC filing
FORM 10-Q FOR JUN 2025
Aug 12, 2025
SEC filing
CURRENT REPORT
May 19, 2025
Earnings release
PRESS RELEASE
May 19, 2025
SEC filing
FORM 10-Q FOR MAR 2025
May 15, 2025
SEC filing
CURRENT REPORT
Apr 02, 2025
Earnings release
PRESS RELEASE
Apr 02, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
Headline from Yahoo Finance: Sunshine Biopharma and University of Arizona Publish Significant New Research Findings.
Form DEF 14A Sunshine Biopharma Inc For: 16 July By Investing.com
Headline from Investing.com Canada: Form DEF 14A Sunshine Biopharma Inc For: 16 July By Investing.com.
Earnings Per Share
Score 2.00/5
Sunshine Biopharma Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Drug Manufacturers Specialty & Generic industry
, Zoetis Inc
, Amphastar P
, Prestige Consumer Healthcare
are companies with high ratings.
Return on Equity
Score 2.91/5
Sunshine Biopharma Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.47/5
Sunshine Biopharma Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 3.04/5
Sunshine Biopharma Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios